{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:31:14Z","timestamp":1785897074656,"version":"3.56.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a second-line treatment with curative potential for leukemia patients. However, the prognosis of allo-HSCT patients with disease relapse or graft-versus-host disease (GvHD) is poor. CD4<jats:sup>+<\/jats:sup> or CD8<jats:sup>+<\/jats:sup> conventional T (Tconv) cells are critically involved in mediating anti-leukemic immune responses to prevent relapse and detrimental GvHD. Hence, treatment for one increases the risk of the other. Thus, therapeutic strategies that can address relapse and GvHD are considered the Holy Grail of allo-HSCT. CD3<jats:sup>+<\/jats:sup>CD4<jats:sup>\u2212<\/jats:sup>CD8<jats:sup>\u2212<\/jats:sup> double-negative T cells (DNTs) are unconventional mature T cells with potent anti-leukemia effects with \u201coff-the-shelf\u201d potential. A phase I clinical trial demonstrated the feasibility, safety, and potential efficacy of allogeneic DNT therapy for patients with relapsing acute myeloid leukemia (AML) post-allo-HSCT. Here, we studied the impact of DNTs on the anti-leukemic and GvHD-inducing activities of Tconv cells. DNTs synergized with Tconv cells to mediate superior anti-leukemic activity. Mechanistically, DNTs released soluble factors which activated and evoked potent anti-leukemic activities of Tconv cells. In contrast, DNTs suppressed GvHD-inducing activities of Tconv cells in a CD18-dependent manner by mediating cytotoxicity against proliferative Tconv cells. The seemingly opposite immunological activities of DNTs were dictated by the presence or absence of AML cells. Collectively, these results support the potential of DNTs as an adjuvant to allo-HSCT to address both disease relapse and GvHD.<\/jats:p>","DOI":"10.1186\/s13046-024-03247-w","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T07:58:22Z","timestamp":1738051102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD"],"prefix":"10.1186","volume":"44","author":[{"given":"Jongbok","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeonjeong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branson","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoosu","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismat","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Housheng Hansen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun D.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Gerbitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"3247_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352. https:\/\/doi.org\/10.1056\/NEJMra1406184.","journal-title":"N Engl J Med"},{"key":"3247_CR2","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1182\/blood.V98.12.3192","volume":"98","author":"VT Ho","year":"2001","unstructured":"Ho VT. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98:3192\u2013204. https:\/\/doi.org\/10.1182\/blood.V98.12.3192.","journal-title":"Blood"},{"key":"3247_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nrclinonc.2014.102","volume":"11","author":"SW Choi","year":"2014","unstructured":"Choi SW, Reddy P. Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol. 2014;11:536\u201347. https:\/\/doi.org\/10.1038\/nrclinonc.2014.102.","journal-title":"Nat Rev Clin Oncol"},{"key":"3247_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555\u201362.","journal-title":"Blood"},{"key":"3247_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/ijms20010228","volume":"20","author":"C Rautenberg","year":"2019","unstructured":"Rautenberg C, Germing U, Haas R, Kobbe G, Schroeder T. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment. Int J Mol Sci. 2019;20:228. https:\/\/doi.org\/10.3390\/ijms20010228.","journal-title":"Int J Mol Sci"},{"key":"3247_CR6","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565\u201379. https:\/\/doi.org\/10.1056\/NEJMra1703472.","journal-title":"N Engl J Med"},{"key":"3247_CR7","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1158\/0008-5472.CAN-16-1311","volume":"76","author":"AK Singh","year":"2016","unstructured":"Singh AK, McGuirk JP. Allogeneic stem cell transplantation: a historical and scientific overview. Cancer Res. 2016;76:6445\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1311.","journal-title":"Cancer Res"},{"key":"3247_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40259-017-0247-0","volume":"31","author":"M Ruella","year":"2017","unstructured":"Ruella M, Kenderian SS. Next-generation chimeric antigen receptor T-cell therapy: going off the shelf. BioDrugs. 2017;31:473\u201381. https:\/\/doi.org\/10.1007\/s40259-017-0247-0.","journal-title":"BioDrugs"},{"key":"3247_CR9","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/mt.2016.106","volume":"24","author":"H Torikai","year":"2016","unstructured":"Torikai H, Cooper LJ. Translational implications for off-the-shelf immune cells expressing chimeric antigen receptors. Mol Ther. 2016;24:1178\u201386. https:\/\/doi.org\/10.1038\/mt.2016.106.","journal-title":"Mol Ther"},{"key":"3247_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","volume":"19","author":"Z Sebestyen","year":"2020","unstructured":"Sebestyen Z, Prinz I, Dechanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (gammadelta) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov. 2020;19:169\u201384. https:\/\/doi.org\/10.1038\/s41573-019-0038-z.","journal-title":"Nat Rev Drug Discov"},{"key":"3247_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.iotech.2019.06.002","volume":"1","author":"O Nussbaumer","year":"2019","unstructured":"Nussbaumer O, Koslowski M. The emerging role of \u03b3\u03b4 T cells in cancer immunotherapy. Immunooncol Technol. 2019;1:3\u201310. https:\/\/doi.org\/10.1016\/j.iotech.2019.06.002.","journal-title":"Immunooncol Technol"},{"key":"3247_CR12","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, Rettig MP, Wang B, Eissenberg LG, Ghobadi A, et al. An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018;32:1970\u201383. https:\/\/doi.org\/10.1038\/s41375-018-0065-5.","journal-title":"Leukemia"},{"key":"3247_CR13","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9:eaaj2013. https:\/\/doi.org\/10.1126\/scitranslmed.aaj2013.","journal-title":"Sci Transl Med"},{"key":"3247_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1517\/14712598.2014.900540","volume":"14","author":"A Marcus","year":"2014","unstructured":"Marcus A, Eshhar Z. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Expert Opin Biol Ther. 2014;14:947\u201354. https:\/\/doi.org\/10.1517\/14712598.2014.900540.","journal-title":"Expert Opin Biol Ther"},{"key":"3247_CR15","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/leu.2011.99","volume":"25","author":"S Merims","year":"2011","unstructured":"Merims S, Li X, Joe B, Dokouhaki P, Han M, Childs RW, Wang ZY, Gupta V, Minden MD, Zhang L. Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy. Leukemia. 2011;25:1415\u201322. https:\/\/doi.org\/10.1038\/leu.2011.99.","journal-title":"Leukemia"},{"key":"3247_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13046-018-0756-9","volume":"37","author":"B Chen","year":"2018","unstructured":"Chen B, Lee JB, Kang H, Minden MD, Zhang L. Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy. J Exp Clin Cancer Res. 2018;37:88. https:\/\/doi.org\/10.1186\/s13046-018-0756-9.","journal-title":"J Exp Clin Cancer Res"},{"key":"3247_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/1078-0432.CCR-17-2228","volume":"24","author":"J Lee","year":"2018","unstructured":"Lee J, Minden MD, Chen WC, Streck E, Chen B, Kang H, Arruda A, Ly D, Der SD, Kang S, et al. Allogeneic human double negative T cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms. Clin Cancer Res. 2018;24:370\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2228.","journal-title":"Clin Cancer Res"},{"key":"3247_CR18","doi-asserted-by":"publisher","unstructured":"Baolin T, Lee JB, Cheng S, Yao W, Wang D, Tu M, Xiang Z, Geng L, Wang M, Qiang P, et al. (2020). Safety and efficacy of ex vivo expanded healthy donor-derived double negative T cells for the treatment of AML relapsed after allogeneic stem cell transplantation: a first in-human Phase I\/IIa clinical trial. Blood. 136:1-2. https:\/\/doi.org\/10.1182\/blood-2020-141505.","DOI":"10.1182\/blood-2020-141505"},{"key":"3247_CR19","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1158\/1078-0432.CCR-18-2291","volume":"25","author":"JB Lee","year":"2019","unstructured":"Lee JB, Kang H, Fang L, D\u2019Souza C, Adeyi O, Zhang L. Developing allogeneic double-negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer. Clin Cancer Res. 2019;25:2241\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2291.","journal-title":"Clin Cancer Res"},{"key":"3247_CR20","doi-asserted-by":"publisher","first-page":"E264","DOI":"10.1002\/ajh.26564","volume":"97","author":"B Tang","year":"2022","unstructured":"Tang B, Lee JB, Cheng S, Pan T, Yao W, Wang D, Tu M, Xiang Z, Chu X, Geng L, et al. Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: a first-in-human phase I study. Am J Hematol. 2022;97:E264\u20137. https:\/\/doi.org\/10.1002\/ajh.26564.","journal-title":"Am J Hematol"},{"key":"3247_CR21","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3389\/fimmu.2018.01943","volume":"9","author":"G Ehx","year":"2018","unstructured":"Ehx G, Somja J, Warnatz HJ, Ritacco C, Hannon M, Delens L, Fransolet G, Delvenne P, Muller J, Beguin Y, et al. Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2\/HHD Mice. Front Immunol. 2018;9:1943. https:\/\/doi.org\/10.3389\/fimmu.2018.01943.","journal-title":"Front Immunol"},{"key":"3247_CR22","doi-asserted-by":"publisher","first-page":"e0133216","DOI":"10.1371\/journal.pone.0133216","volume":"10","author":"H Fujii","year":"2015","unstructured":"Fujii H, Luo ZJ, Kim HJ, Newbigging S, Gassas A, Keating A, Egeler RM. Humanized chronic graft-versus-host disease in NOD-SCID il2rgamma-\/- (NSG) mice with G-CSF-mobilized peripheral blood mononuclear cells following cyclophosphamide and total body irradiation. PLoS One. 2015;10:e0133216. https:\/\/doi.org\/10.1371\/journal.pone.0133216.","journal-title":"PLoS ONE"},{"key":"3247_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","volume":"27","author":"X Cao","year":"2007","unstructured":"Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27:635\u201346. https:\/\/doi.org\/10.1016\/j.immuni.2007.08.014.","journal-title":"Immunity"},{"key":"3247_CR24","doi-asserted-by":"publisher","first-page":"1335341","DOI":"10.3389\/fimmu.2024.1335341","volume":"15","author":"EAS Koster","year":"2024","unstructured":"Koster EAS, von dem Borne PA, van Balen P, Marijt EWA, Tjon JML, Snijders TJF, van Lammeren D, Veelken H, Falkenburg JHF, Halkes CJM, de Wreede LC. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation. Front Immunol. 2024;15:1335341. https:\/\/doi.org\/10.3389\/fimmu.2024.1335341.","journal-title":"Front Immunol"},{"key":"3247_CR25","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.jtct.2023.12.080","volume":"30","author":"A Nagler","year":"2024","unstructured":"Nagler A, Ngoya M, Galimard J-E, Labopin M, Blau W-I, Kroger N, Gedde-Dahl T, Schroeder T, Burns D, Salmenniemi U, et al. Relapse incidence post unrelated allogeneic stem cell transplantation with Post-Transplant Cyclophosphamide (PTCy) in patients with acute myeloid leukemia: a study on behalf of the acute leukemia working party of the European society for blood and marrow transplantation. Transplant Cell Ther. 2024;30:S46\u20137. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.080.","journal-title":"Transplant Cell Ther"},{"key":"3247_CR26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","volume":"124","author":"MF Martelli","year":"2014","unstructured":"Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, Pierini A, Massei MS, Amico L, Urbani E, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124:638\u201344. https:\/\/doi.org\/10.1182\/blood-2014-03-564401.","journal-title":"Blood"},{"key":"3247_CR27","doi-asserted-by":"publisher","first-page":"1081644","DOI":"10.3389\/fcell.2022.1081644","volume":"10","author":"L Amini","year":"2022","unstructured":"Amini L, Kaeda J, Fritsche E, Roemhild A, Kaiser D, Reinke P. Clinical adoptive regulatory T Cell therapy: state of the art, challenges, and prospective. Front Cell Dev Biol. 2022;10:1081644. https:\/\/doi.org\/10.3389\/fcell.2022.1081644.","journal-title":"Front Cell Dev Biol"},{"key":"3247_CR28","doi-asserted-by":"publisher","first-page":"eabl3642","DOI":"10.1126\/sciimmunol.abl3642","volume":"7","author":"D Vasic","year":"2022","unstructured":"Vasic D, Lee JB, Leung Y, Khatri I, Na Y, Abate-Daga D, Zhang L. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. Sci Immunol. 2022;7:eabl3642. https:\/\/doi.org\/10.1126\/sciimmunol.abl3642.","journal-title":"Sci Immunol"},{"key":"3247_CR29","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nri2654","volume":"9","author":"JA Bluestone","year":"2009","unstructured":"Bluestone JA, Mackay CR, O\u2019Shea JJ, Stockinger B. The functional plasticity of T cell subsets. Nat Rev Immunol. 2009;9:811\u20136. https:\/\/doi.org\/10.1038\/nri2654.","journal-title":"Nat Rev Immunol"},{"key":"3247_CR30","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3389\/fimmu.2019.01563","volume":"10","author":"N Bercovici","year":"2019","unstructured":"Bercovici N, Guerin MV, Trautmann A, Donnadieu E. The remarkable plasticity of macrophages: a chance to fight cancer. Front Immunol. 2019;10:1563. https:\/\/doi.org\/10.3389\/fimmu.2019.01563.","journal-title":"Front Immunol"},{"key":"3247_CR31","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1172\/JCI91138","volume":"127","author":"X Ni","year":"2017","unstructured":"Ni X, Song Q, Cassady K, Deng R, Jin H, Zhang M, Dong H, Forman S, Martin PJ, Chen YZ, et al. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. J Clin Invest. 2017;127:1960\u201377. https:\/\/doi.org\/10.1172\/JCI91138.","journal-title":"J Clin Invest"},{"key":"3247_CR32","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1096\/fj.201800636R","volume":"33","author":"MA Brehm","year":"2019","unstructured":"Brehm MA, Kenney LL, Wiles MV, Low BE, Tisch RM, Burzenski L, Mueller C, Greiner DL, Shultz LD. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. FASEB J. 2019;33:3137\u201351. https:\/\/doi.org\/10.1096\/fj.201800636R.","journal-title":"FASEB J"},{"key":"3247_CR33","doi-asserted-by":"publisher","first-page":"816005","DOI":"10.3389\/fimmu.2022.816005","volume":"13","author":"Z Wu","year":"2022","unstructured":"Wu Z, Zheng Y, Sheng J, Han Y, Yang Y, Pan H, Yao J. CD3(+)CD4(-)CD8(-) (Double-Negative) T cells in inflammation, immune disorders and cancer. Front Immunol. 2022;13:816005. https:\/\/doi.org\/10.3389\/fimmu.2022.816005.","journal-title":"Front Immunol"},{"key":"3247_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.seminhematol.2023.02.003","volume":"60","author":"JC Gea-Banacloche","year":"2023","unstructured":"Gea-Banacloche JC. Infectious complications of chimeric antigen receptor (CAR) T-cell therapies. Semin Hematol. 2023;60:52\u20138. https:\/\/doi.org\/10.1053\/j.seminhematol.2023.02.003.","journal-title":"Semin Hematol"},{"key":"3247_CR35","doi-asserted-by":"publisher","unstructured":"Kaminski J, Fleming RA, Alvarez-Calderon F, Winschel MB, McGuckin C, Ho EE, Eng F, Rui X, Keskula P, Cagnin L, et al. B-cell-directed CAR-T cell therapy activates CD8+ cytotoxic CARneg bystander T-cells in non-human primates and patients. Blood. 2024. https:\/\/doi.org\/10.1182\/blood.2023022717.","DOI":"10.1182\/blood.2023022717"},{"key":"3247_CR36","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s43018-023-00600-4","volume":"4","author":"EC Lerner","year":"2023","unstructured":"Lerner EC, Woroniecka KI, D\u2019Anniballe VM, Wilkinson DS, Mohan AA, Lorrey SJ, Waibl-Polania J, Wachsmuth LP, Miggelbrink AM, Jackson JD, et al. CD8(+) T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis. Nat Cancer. 2023;4:1258\u201372. https:\/\/doi.org\/10.1038\/s43018-023-00600-4.","journal-title":"Nat Cancer"},{"key":"3247_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1365-2141.2008.07021.x","volume":"141","author":"Z McIver","year":"2008","unstructured":"McIver Z, Serio B, Dunbar A, O\u2019Keefe CL, Powers J, Wlodarski M, Jin T, Sobecks R, Bolwell B, Maciejewski JP. Double-negative regulatory T cells induce allotolerance when expanded after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2008;141:170\u20138. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07021.x.","journal-title":"Br J Haematol"},{"key":"3247_CR38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/bmt.2016.238","volume":"52","author":"Z Bian","year":"2017","unstructured":"Bian Z, Liu J, Xu LP, Chang YJ, Wang Y, Zhang XH, Huang XJ. Association of Epstein-Barr virus reactivation with the recovery of CD4\/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:264\u20139. https:\/\/doi.org\/10.1038\/bmt.2016.238.","journal-title":"Bone Marrow Transplant"},{"key":"3247_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bbmt.2018.09.008","volume":"25","author":"EE Hillhouse","year":"2019","unstructured":"Hillhouse EE, Thiant S, Moutuou MM, Lombard-Vadnais F, Parat R, Delisle JS, Ahmad I, Roy DC, Guimond M, Roy J, Lesage S. Double-negative T cell levels correlate with chronic graft-versus-host disease severity. Biol Blood Marrow Transplant. 2019;25:19\u201325. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.008.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3247_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/BOR.0000000000000778","volume":"33","author":"H Li","year":"2021","unstructured":"Li H, Tsokos GC. Double-negative T cells in autoimmune diseases. Curr Opin Rheumatol. 2021;33:163\u201372. https:\/\/doi.org\/10.1097\/BOR.0000000000000778.","journal-title":"Curr Opin Rheumatol"},{"key":"3247_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/jmcb\/mjr043","volume":"4","author":"SC Juvet","year":"2012","unstructured":"Juvet SC, Zhang L. Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions. J Mol Cell Biol. 2012;4:48\u201358. https:\/\/doi.org\/10.1093\/jmcb\/mjr043.","journal-title":"J Mol Cell Biol"},{"key":"3247_CR42","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cell.2019.05.047","volume":"178","author":"A Ponzetta","year":"2019","unstructured":"Ponzetta A, Carriero R, Carnevale S, Barbagallo M, Molgora M, Perucchini C, Magrini E, Gianni F, Kunderfranco P, Polentarutti N, et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors. Cell. 2019;178:346-360 e324. https:\/\/doi.org\/10.1016\/j.cell.2019.05.047.","journal-title":"Cell"},{"key":"3247_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-019-0507-2","volume":"7","author":"J Yao","year":"2019","unstructured":"Yao J, Ly D, Dervovic D, Fang L, Lee JB, Kang H, Wang YH, Pham NA, Pan H, Tsao MS, Zhang L. Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. J Immunother Cancer. 2019;7:17. https:\/\/doi.org\/10.1186\/s40425-019-0507-2.","journal-title":"J Immunother Cancer"},{"key":"3247_CR44","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1172\/JCI66301","volume":"123","author":"A Ghosh","year":"2013","unstructured":"Ghosh A, Dogan Y, Moroz M, Holland AM, Yim NL, Rao UK, Young LF, Tannenbaum D, Masih D, Velardi E, et al. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. J Clin Invest. 2013;123:2654\u201362. https:\/\/doi.org\/10.1172\/JCI66301.","journal-title":"J Clin Invest"},{"key":"3247_CR45","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","volume":"115","author":"JA Olson","year":"2010","unstructured":"Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115:4293\u2013301. https:\/\/doi.org\/10.1182\/blood-2009-05-222190.","journal-title":"Blood"},{"key":"3247_CR46","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3389\/fimmu.2018.00952","volume":"9","author":"BL Walling","year":"2018","unstructured":"Walling BL, Kim M. LFA-1 in T cell migration and differentiation. Front Immunol. 2018;9:952. https:\/\/doi.org\/10.3389\/fimmu.2018.00952.","journal-title":"Front Immunol"},{"key":"3247_CR47","doi-asserted-by":"publisher","first-page":"e0232432","DOI":"10.1371\/journal.pone.0232432","volume":"15","author":"S Lukacsi","year":"2020","unstructured":"Lukacsi S, Gerecsei T, Balazs K, Francz B, Szabo B, Erdei A, Bajtay Z. The differential role of CR3 (CD11b\/CD18) and CR4 (CD11c\/CD18) in the adherence, migration and podosome formation of human macrophages and dendritic cells under inflammatory conditions. PLoS One. 2020;15:e0232432. https:\/\/doi.org\/10.1371\/journal.pone.0232432.","journal-title":"PLoS ONE"},{"key":"3247_CR48","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/j.ajpath.2016.04.001","volume":"186","author":"NP Podolnikova","year":"2016","unstructured":"Podolnikova NP, Kushchayeva YS, Wu Y, Faust J, Ugarova TP. The Role of Integrins alphaMbeta2 (Mac-1, CD11b\/CD18) and alphaDbeta2 (CD11d\/CD18) in Macrophage Fusion. Am J Pathol. 2016;186:2105\u201316. https:\/\/doi.org\/10.1016\/j.ajpath.2016.04.001.","journal-title":"Am J Pathol"},{"key":"3247_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/cancers9110153","volume":"9","author":"M Reina","year":"2017","unstructured":"Reina M, Espel E. Role of LFA-1 and ICAM-1 in cancer. Cancers (Basel). 2017;9:153. https:\/\/doi.org\/10.3390\/cancers9110153.","journal-title":"Cancers (Basel)"},{"key":"3247_CR50","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.molimm.2009.04.004","volume":"46","author":"J Wohler","year":"2009","unstructured":"Wohler J, Bullard D, Schoeb T, Barnum S. LFA-1 is critical for regulatory T cell homeostasis and function. Mol Immunol. 2009;46:2424\u20138. https:\/\/doi.org\/10.1016\/j.molimm.2009.04.004.","journal-title":"Mol Immunol"},{"key":"3247_CR51","doi-asserted-by":"publisher","first-page":"10113","DOI":"10.1073\/pnas.0711106105","volume":"105","author":"Y Onishi","year":"2008","unstructured":"Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008;105:10113\u20138. https:\/\/doi.org\/10.1073\/pnas.0711106105.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3247_CR52","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.4049\/jimmunol.1700495","volume":"199","author":"NK Verma","year":"2017","unstructured":"Verma NK, Kelleher D. Not just an adhesion molecule: LFA-1 contact tunes the T lymphocyte program. J Immunol. 2017;199:1213\u201321. https:\/\/doi.org\/10.4049\/jimmunol.1700495.","journal-title":"J Immunol"},{"key":"3247_CR53","doi-asserted-by":"publisher","first-page":"21001","DOI":"10.1074\/jbc.M109.002865","volume":"284","author":"D Li","year":"2009","unstructured":"Li D, Molldrem JJ, Ma Q. LFA-1 regulates CD8+ T cell activation via T cell receptor-mediated and LFA-1-mediated Erk1\/2 signal pathways. J Biol Chem. 2009;284:21001\u201310. https:\/\/doi.org\/10.1074\/jbc.M109.002865.","journal-title":"J Biol Chem"},{"key":"3247_CR54","doi-asserted-by":"publisher","unstructured":"Boulch M, Cazaux M, Cuffel A, Guerin MV, Garcia Z, Alonso R, Lemaitre F, Beer A, Corre B, Menger L, et al. Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-gamma is a major determinant of CD4(+) CAR T-cell antitumor activity. Nat Cancer. 2023. https:\/\/doi.org\/10.1038\/s43018-023-00570-7.","DOI":"10.1038\/s43018-023-00570-7"},{"key":"3247_CR55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022;602:503\u20139. https:\/\/doi.org\/10.1038\/s41586-021-04390-6.","journal-title":"Nature"},{"key":"3247_CR56","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","volume":"69","author":"H Harlin","year":"2009","unstructured":"Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69:3077\u201385. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2281.","journal-title":"Cancer Res"},{"key":"3247_CR57","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1128\/jvi.77.7.4004-4014.2003","volume":"77","author":"MJ Trifilo","year":"2003","unstructured":"Trifilo MJ, Bergmann CC, Kuziel WA, Lane TE. CC chemokine ligand 3 (CCL3) regulates CD8(+)-T-cell effector function and migration following viral infection. J Virol. 2003;77:4004\u201314. https:\/\/doi.org\/10.1128\/jvi.77.7.4004-4014.2003.","journal-title":"J Virol"},{"key":"3247_CR58","doi-asserted-by":"publisher","first-page":"e137263","DOI":"10.1172\/jci.insight.137263","volume":"5","author":"AP Huffman","year":"2020","unstructured":"Huffman AP, Lin JH, Kim SI, Byrne KT, Vonderheide RH. CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity. JCI Insight. 2020;5:e137263. https:\/\/doi.org\/10.1172\/jci.insight.137263.","journal-title":"JCI Insight"},{"key":"3247_CR59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/MOH.0000000000000626","volume":"28","author":"JS Romer-Seibert","year":"2021","unstructured":"Romer-Seibert JS, Meyer SE. Genetic heterogeneity and clonal evolution in acute myeloid leukemia. Curr Opin Hematol. 2021;28:64\u201370. https:\/\/doi.org\/10.1097\/MOH.0000000000000626.","journal-title":"Curr Opin Hematol"},{"key":"3247_CR60","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009081","author":"J Lee","year":"2021","unstructured":"Lee J, Khan DH, Hurren R, Xu M, Na Y, Kang H, Mirali S, Wang X, Gronda MV, Jitkova Y, et al. Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. Blood. 2021. https:\/\/doi.org\/10.1182\/blood.2020009081.","journal-title":"Blood"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03247-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03247-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03247-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T07:58:25Z","timestamp":1738051105000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03247-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3247"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03247-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All of the authors concur with the submission of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L.Z. has financial interests (e.g., holdings\/shares) in WYZE Biotech Co Ltd and previously received research funding and consulting fee\/honorarium from the Company. L.Z., J.B.L and H.K. are inventors of several patents related to DNT cell technology, and L.Z. received license fees. The remaining authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}